Appendix Table 2: Sensitivity analyses by study quality and duration in clinical trials assessing the benefits and harms of pregabalin in neuropathic pain

Outcome	Sensitivity analysis based on higher quality studies*	Sensitivity analysis based on shorter duration of intervention**	Sensitivity analysis based on longer duration of intervention***
Pain	5 studies (n = 932): SMD -0.56 (-1.07 to -0.05; P = 0.03; I^2=92%)	10 studies (n = 2408): SMD -0.68 (-0.96 to -0.40; P < 0.00001; I^2=90%)	10 studies (n = 2685): SMD -0.31 (-0.49 to -0.13; P = 0.0006; I^2=79%)
Adverse events	6 studies (n = 1152): RR 1.17 (1.06 to 1.29; P = 0.002; I^2=23%)	11 studies (n = 2088): RR 1.46 (1.34 to 1.58; P < 0.00001; I^2=0%)	8 studies (n = 1922): RR 1.23 (1.12 to 1.35; P < 0.0001; I^2=55%)
Serious adverse events	3 studies (n = 627): RR 0.59 (0.38 to 0.92; P = 0.02; I^2=0%)	8 studies (n = 2088): RR 0.72 (0.49 to 1.07; P = 0.11; I^2=0%)	7 studies (n = 1674): RR 0.93 (0.55 to 1.59; P = 0.79; I^2=26%)
Discontinuation due to adverse events	6 studies (n = 1152): RR 1.22 (0.79 to 1.87; P = 0.37; I^2=0%)	13 studies (n = 2403): RR 1.95 (1.34 to 2.84; P = 0.0005; I^2=27%)	11 studies (n = 3023): RR 1.88 (1.40 to 2.53; P < 0.0001; I^2=0%)

*Studies that adequately reported randomization and blinding procedures
**Studies duration lasting less than 12 weeks
***Studies duration lasting at least 12 weeks